JPH04321684A - 2-pyridone compound - Google Patents
2-pyridone compoundInfo
- Publication number
- JPH04321684A JPH04321684A JP3182111A JP18211191A JPH04321684A JP H04321684 A JPH04321684 A JP H04321684A JP 3182111 A JP3182111 A JP 3182111A JP 18211191 A JP18211191 A JP 18211191A JP H04321684 A JPH04321684 A JP H04321684A
- Authority
- JP
- Japan
- Prior art keywords
- culture
- strain
- methanol
- medium
- chloroform
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【0001】0001
【産業上の利用分野】本発明は抗真菌作用及び抗腫瘍作
用を有する2−ピリドン系化合物に関する。FIELD OF THE INVENTION The present invention relates to 2-pyridone compounds having antifungal and antitumor effects.
【0002】0002
【従来の技術】従来、本発明の化合物に構造類似で同様
の生理活性を有する化合物は知られていない。BACKGROUND OF THE INVENTION Hitherto, no compounds have been known that are structurally similar to the compounds of the present invention and have similar physiological activities.
【0003】0003
【発明が解決しようとする課題】本発明の目的は、優れ
た抗真菌作用及び抗腫瘍作用を有する新規な化合物を供
給し、ひいては抗真菌剤及び抗癌剤として患者の治療に
役立てることにある。OBJECTS OF THE INVENTION An object of the present invention is to provide a novel compound having excellent antifungal and antitumor effects, and to use the compound as an antifungal and anticancer agent in the treatment of patients.
【0004】0004
【課題を解決するための手段】本発明者らは、前記目的
の達成のために多数の菌株を植物及び土壌よリ分離し、
その菌株の代謝産物について種々検討した結果、ある種
の菌株が、真菌及び癌培養細胞に対して増殖抑制作用を
有する新規な生理活性物質を生産することを見いだし本
発明を完成するに至った。すなわち、本発明は、[Means for Solving the Problems] In order to achieve the above object, the present inventors isolated a large number of bacterial strains from plants and soil,
As a result of various studies on the metabolites of the strain, it was discovered that a certain strain produces a novel physiologically active substance that has a growth-inhibitory effect on fungi and cultured cancer cells, leading to the completion of the present invention. That is, the present invention
【00
05】00
05]
【化2】
で表される化合物(以下、AF−110と称する。)で
ある。This is a compound represented by the following formula (hereinafter referred to as AF-110).
【0006】本発明のAF−110を生産する微生物は
、本発明者らが埼玉県大宮市吉野町で採取した松かさよ
り新たに分離した菌株であリ、微生物の名称「Peni
cillium sp.F−4209」及び微生物寄
託番号「微工研菌寄第12163号(FERM P−
12163)」として、工業技術院微生物工業技術研究
所に寄託されている。The microorganism producing AF-110 of the present invention is a strain newly isolated by the present inventors from a pine cone collected in Yoshino-cho, Omiya City, Saitama Prefecture, and the microorganism is named "Peni".
cilium sp. F-4209” and microorganism deposit number “FERM P-
12163)" and has been deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology.
【0007】この菌株の菌学的性状を以下に示す。
[形態]本菌株は、麦芽エキス寒天培地,バレイシヨ・
ブドウ糖寒天培地,オートミール寒天培地,YpSs寒
天培地等で中程度に生育し、胞子の形成も中程度である
。本菌株がバレイショ・ブドウ糖寒天培地上、25℃、
14日間の培養で形成したコロニーを顕微鏡下で観察す
ると、菌糸は白色で隔壁を有し、高度に分枝している。
分生子形成細胞は、菌糸あるいはゆるい菌糸束から分枝
して立ち上がった分生子柄の先端に、メトレ(Metr
e)を介して二段階、あるいはより複雑に分枝して形成
されており、ペニシリウム属に特徴的な、ペニシリ(P
enicilli) と呼ばれる形態が観察される。
分生子柄は隔壁を有し、表面は滑面、その径は2.5〜
3.8μm、長さは15〜70μmである。メトレ
は分生子柄の先端部分から3〜8本が比較的狭い角度で
輪生し、その表面は滑面、大きさは10.0〜16.0
μm×2.0〜3.0μmである。フィアライドは先端
が先細りのフラスコ型で表面は滑面、大きさは12.0
〜15.0μm×1.6〜2.0μmである。分生子は
亜球形からまれに球形を呈し、表面は滑面、大きさは1
.8〜4.0μm×1.8〜3.0μmである。尚、培
養を1ヵ月以上延長して、観察を続けたところ、子のう
などの有性生殖器官の形成は認められなかったが、コロ
ニーの一部に分生子柄束(Coremia)形成が観察
された。[0007] The mycological properties of this strain are shown below. [Morphology] This strain can be used on malt extract agar medium, potato
It grows moderately on glucose agar, oatmeal agar, YpSs agar, etc., and forms spores at a moderate rate. This strain was grown on potato-glucose agar medium at 25°C.
When colonies formed after 14 days of culture were observed under a microscope, the hyphae were white, had septa, and were highly branched. Conidiogenic cells are present at the tips of conidiophores that branch out and stand up from hyphae or loose hyphal bundles.
Penicillium (P
enicilli) is observed. The conidiophore has septa, the surface is smooth, and the diameter is 2.5~
3.8 μm, and the length is 15 to 70 μm. Metoles have 3 to 8 whorls at a relatively narrow angle from the tip of the conidiophore, the surface is smooth, and the size is 10.0 to 16.0.
It is μm×2.0 to 3.0 μm. Phialide has a flask shape with a tapered tip, a smooth surface, and a size of 12.0
~15.0 μm×1.6 to 2.0 μm. Conidia are subglobose to rarely spherical, with a smooth surface and a size of 1
.. It is 8-4.0 micrometers x 1.8-3.0 micrometers. Furthermore, when the culture was extended for more than one month and observation was continued, the formation of sexual reproductive organs such as ascus was not observed, but the formation of conidiophore bundles (Coremia) was observed in some of the colonies. It was done.
【0008】[培地上での諸性状]各種培地上で、25
℃,14日間培養したときの肉眼による観察結果を表1
に示す。[Properties on medium] On various medium, 25
Table 1 shows the results of visual observation when cultured at ℃ for 14 days.
Shown below.
【0009】[0009]
【表1】[Table 1]
【0010】[生理的性質]
1)生育pH範囲及び最適pH
本菌株はYpSs培地において、pH2〜7の範囲で生
育し、最適pHは3〜6である。
2)生育温度範囲及び最適温度
本菌株はサブロー培地において、10〜37℃の範囲で
生育し、最適温度は25〜34℃である。
3)好気性,嫌気性の区別:好気性[Physiological properties] 1) Growth pH range and optimum pH This strain grows in a YpSs medium in a pH range of 2 to 7, with an optimum pH of 3 to 6. 2) Growth temperature range and optimum temperature This strain grows in the Sabouraud medium at a temperature range of 10 to 37°C, and the optimum temperature is 25 to 34°C. 3) Distinction between aerobic and anaerobic: aerobic
【0011】以上の形態的特徴及び培養上の性状から、
本菌株が不完全菌Penicillium属に属するこ
とが明らかとなったので、前記諸性状を基に、宇田川俊
一,椿啓介編『菌類図鑑』(1978年)、K.B.R
aper,C.Thom著「A MANUAL O
F THE PENICILLIA」(1949年
)及びJ.I.Pitt著 「A LABORAT
ORY GUIDETO COMMON Pen
icillium SPECIES」(1985年)
に報告されている多くの既知菌株と比較検討した。その
結果、本菌株はCoremiaの形成という点でPen
icillium vulpinumに、またその他
の点ではPenicillium funiculo
sumに最も近い性状を示すことが明らかとなった。し
かし、文献上の記載と照合した結果、Penicill
ium vulpinumとは本菌株が37℃で生育
することやフィアライドや分生子の形状,大きさ等で異
なり、−方Penicillium funicul
osumとはメトレやフィアライド、分生子等の大きさ
や、コロニー性状等において若干異なる点がみられた。
従って、本菌株が上記2菌種のいずれかであるかあるい
は或はその変種という可能性が示唆されたが、決定的な
根拠がないので本菌株をPenicillium s
p.F−4209と命名した。From the above morphological characteristics and culture properties,
It has become clear that this strain belongs to the genus Penicillium, and based on the above-mentioned properties, it was determined that the present strain belongs to the Deuteromycetes genus Penicillium. B. R
aper, C. “A MANUAL O” by Thom
F THE PENICILLIA” (1949) and J. I. Written by Pitt “A LABORAT”
ORY GUIDETO COMMON Pen
icilium SPECIES” (1985)
A comparison study was made with many known bacterial strains reported in As a result, this strain was found to be more effective in terms of Coremia formation.
icilium vulpinum, and in other respects Penicillium funiculo
It has become clear that the properties are closest to those of sum. However, as a result of checking with descriptions in the literature, Penicill
This strain differs from Penicillium funicul in that it grows at 37°C and in the shape and size of phialides and conidia.
There were some differences from Osum in the size of metres, phialides, conidia, etc., and colony properties. Therefore, it has been suggested that this strain may be one of the above two bacterial species or a variant thereof, but as there is no conclusive evidence, this strain has been classified as Penicillium spp.
p. It was named F-4209.
【0012】AF−110の生産は、大略一般の抗生物
質を生産する場合に準じ、各種栄養物質を含む培地でA
F−110生産菌株であるPenicillium
sp.F−4209を好気的条件下で培養することによ
り行う。培地は液体培地が好ましく、主として炭棄源、
窒素源、無機塩よりなり、必要に応じてビタミン類、先
駆物質、消泡剤を加えることができ、pHは6前後に調
整する。炭素源としては、例えばグルコース、マルトー
ス、デキストリン、グリセリン、澱粉などを単独かまた
は混合して用いる。窒素源としては、例えば酵母エキス
、ペプトン、肉エキス、大豆粉、コーン・スティー・リ
カー、尿素、アンモニウム塩などを単独かまたは混合し
て用いる。無機塩としては、例えば燐酸−カリウム、硫
酸マグネシウム、塩化ナトリウム、炭酸カルシウムなど
を単独かまたは混合して用いる。消泡剤としてはアデカ
ノール、シリコン化合物などを用いることができる。The production of AF-110 is roughly similar to the production of general antibiotics, in which AF-110 is produced in a medium containing various nutritional substances.
F-110 producing strain Penicillium
sp. This is done by culturing F-4209 under aerobic conditions. The medium is preferably a liquid medium, mainly containing charcoal sources,
It consists of a nitrogen source and inorganic salts, and if necessary, vitamins, precursors, and antifoaming agents can be added, and the pH is adjusted to around 6. As the carbon source, for example, glucose, maltose, dextrin, glycerin, starch, etc. are used alone or in combination. As the nitrogen source, for example, yeast extract, peptone, meat extract, soybean flour, corn tea liquor, urea, ammonium salt, etc. are used alone or in combination. Examples of inorganic salts include potassium phosphate, magnesium sulfate, sodium chloride, and calcium carbonate, which may be used alone or in combination. Adekanol, a silicon compound, etc. can be used as an antifoaming agent.
【0013】培養方法としては振盪培養、通気撹拌培養
などの好気的培養が適しており、pH6前後で25〜3
4℃、望ましくは25〜30℃で培養する。この培養に
より生産されたAF−110のほとんどが菌体内に蓄積
されることから、例えば次の方法により単離することが
できる。すなわち、培養終了後、遠心分離及び濾過によ
り分離した菌体からAF−110を低級アルコール、ア
セトンなどの有機溶媒で抽出し、この抽出液を減圧濃縮
し有機溶媒を除去した後、酢酸エチル、ベンゼン、クロ
ロホルムなどの非水溶性有機溶媒に転溶し、これを減圧
濃縮してシロップ状とする。このシロップを再度酢酸エ
チル、ベンゼン、クロロホルム、アセトン、メタノール
などの有機溶媒に溶解し、シリカゲルを用いたカラムク
ロマトグラフィー、ODSカラムを用いた高速液体クロ
マトグラフィー及びセファデックスLH−20(商品名
、ファルマシア社製)を用いたゲル濾過に付すことによ
りAF−110を淡黄色粉末として単離することができ
る。[0013] As a culture method, aerobic culture such as shaking culture and aerated agitation culture is suitable.
Culture at 4°C, preferably 25-30°C. Since most of the AF-110 produced by this culture is accumulated within the bacterial cells, it can be isolated, for example, by the following method. That is, after completion of the culture, AF-110 is extracted from the bacterial cells separated by centrifugation and filtration with an organic solvent such as a lower alcohol or acetone, and this extract is concentrated under reduced pressure to remove the organic solvent. , transferred to a water-insoluble organic solvent such as chloroform, and concentrated under reduced pressure to form a syrup. This syrup was dissolved again in an organic solvent such as ethyl acetate, benzene, chloroform, acetone, and methanol, and subjected to column chromatography using silica gel, high performance liquid chromatography using an ODS column, and Sephadex LH-20 (trade name, Pharmacia). AF-110 can be isolated as a pale yellow powder by gel filtration using a gel filtration solution (manufactured by Phys. Co., Ltd.).
【0014】以上の精製によって得られた本発明の目的
物質であるAF−110は、その元素分析値、分子量、
紫外線吸収スペクトル、1H一NMRスペクトル、13
C−NMRスペクトル等の解析結果より化2のように構
造式が決定された。AF−110の理化学的性質は以下
の通りである。
(a)元素分析値:
実測値(%) C 67.05,H 8.56,
N 2.99
理論値(%) C 68.21,H 8.63,
N 2.95
(C27H41NO6で計算)
(b)FABマススペクトル:
FAB(+) m/z 476(M+H)+ F
AB(−) m/z 474(M−H)−(c)分
子量:475
(d)融点:86〜89℃
(e)比旋光度:
[a]D25=−184°(c=0.1,メタノール)
(f)紫外線吸収スペクトル:
λmax 290nm(ε=6700)λmax
213nm(ε=34000)(メタノール溶液中で測
定)なお、測定結果を図1に併せて示す。
(g)赤外線吸収スペクトル:臭化カリウム錠中で測定
した結果を図2に示す。
(h)1H−NMRスペクトル:重ジメチルスルホオキ
サイド中、400MHzで測定した結果を図3に示す。
(i)13C−NMRスペクトル:重ジメチルスルホオ
キサイド中、100MHzで測定した結果を図4に示す
。
(j)溶剤に対する溶解性:水に不溶。メタノール、ア
セトン、クロロホルム、酢酸エチルに難溶。ジメチルス
ルホオキサイドに易溶。
(k)呈色反応;
陽性:硫酸、ヨウ素。
陰性:ニンヒドリン、塩化第一鉄。
(l)塩基性、酸性、中性の区別:中性(m)物質の色
:淡黄色粉末AF-110, which is the target substance of the present invention obtained through the above purification, has the following elemental analysis values, molecular weight,
Ultraviolet absorption spectrum, 1H-NMR spectrum, 13
The structural formula as shown in Chemical Formula 2 was determined from the analysis results such as C-NMR spectrum. The physical and chemical properties of AF-110 are as follows. (a) Elemental analysis value: Actual value (%) C 67.05, H 8.56,
N 2.99 Theoretical value (%) C 68.21, H 8.63,
N 2.95 (calculated using C27H41NO6) (b) FAB mass spectrum: FAB (+) m/z 476 (M+H) + F
AB(-) m/z 474(MH)-(c) Molecular weight: 475 (d) Melting point: 86-89°C (e) Specific optical rotation: [a] D25 = -184° (c = 0.1 ,methanol)
(f) Ultraviolet absorption spectrum: λmax 290nm (ε=6700) λmax
213 nm (ε=34000) (measured in methanol solution) The measurement results are also shown in FIG. (g) Infrared absorption spectrum: The results measured in potassium bromide tablets are shown in FIG. (h) 1H-NMR spectrum: The results of measurement at 400 MHz in deuterated dimethyl sulfoxide are shown in FIG. (i) 13C-NMR spectrum: The results of measurement at 100 MHz in deuterated dimethyl sulfoxide are shown in FIG. (j) Solubility in solvents: Insoluble in water. Slightly soluble in methanol, acetone, chloroform, and ethyl acetate. Easily soluble in dimethyl sulfoxide. (k) Color reaction; Positive: sulfuric acid, iodine. Negative: ninhydrin, ferrous chloride. (l) Basic, acidic, neutral: Neutral (m) Color of substance: pale yellow powder
【0015】[0015]
【発明の効果】本発明の化合物は、細菌、酵母、糸状菌
及び癌培養細胞に対し増殖抑制作用を有するので、真菌
症、癌疾患の治療に役立てることができる。EFFECTS OF THE INVENTION The compounds of the present invention have a growth-inhibitory effect on bacteria, yeast, filamentous fungi, and cultured cancer cells, and therefore can be useful in the treatment of mycoses and cancer diseases.
【0016】[0016]
【実施例】以下、実施例及び試験例を示し、本発明を更
に詳細に説明する。
実施例
100ml当りグルコース2g、ポリペプトン0.5g
、酵母エキス0.3g、リン酸−カリウム0.1g、硫
酸マグネシウム0.05gからなるpH6の無菌液体培
地にPenicillium sp.F−4209株
を接種し、28℃、72時間振盪培養した。次に200
L容培養タンクを用いて、種培養と同じ組成の無菌培地
120Lに前記種培養液1.2Lを接種し28℃、96
時間撹拌通気培養した。培養終了後遠心分離機で上澄液
と菌体に分けた。得られた菌体8.5kgをアセトン1
5Lで2回抽出し、この抽出液を合わせ減圧濃縮してア
セトンを徐去した後、半量の酢酸エチルで2回抽出した
。この酢酸エチル抽出区分を合わせ無水硫酸ナトリウム
で脱水後、滅圧濃縮乾固し褐色シロップ24gを得た。[Examples] The present invention will be explained in more detail below with reference to Examples and Test Examples. Example 2g of glucose and 0.5g of polypeptone per 100ml
Penicillium sp. F-4209 strain was inoculated and cultured with shaking at 28°C for 72 hours. then 200
Using a L-capacity culture tank, 120 L of a sterile medium with the same composition as the seed culture was inoculated with 1.2 L of the seed culture solution and incubated at 28°C at 96°C.
Cultured with agitation for hours. After the culture was completed, the supernatant and the bacterial cells were separated using a centrifuge. 8.5 kg of the obtained bacterial cells were mixed with 1 part of acetone.
The mixture was extracted twice with 5 L, and the extracts were combined and concentrated under reduced pressure to gradually remove acetone, and then extracted twice with half the amount of ethyl acetate. The ethyl acetate extracted fractions were combined, dehydrated over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure to obtain 24 g of brown syrup.
【0017】この褐色シロップをクロロホルム200m
lに溶解し、クロロホルムで調製したシリカゲル[ワコ
ーゲルC−200(商品名、和光純薬社製)]の500
mlカラムに吸着させた。クロロホルム500mlで洗
浄後、クロロホルム−メタノール(95:5)の混合溶
媒で溶出し、この区分を除去した。次にクロロホルム−
メタノール(90:10)の混合溶媒で溶出を行い、フ
ラクションコレクターを用い1フラクション20gつづ
分画した。各フラクションのカンジダ・アルビカンスに
対する抗菌活性をペーパーディスク法で確認後、活性の
認められた区分を集め減圧濃縮乾固し、AF−110の
粗精製粉末1.5gを得た。シリカゲルカラム精製で得
られたAF−110の粗粉末をメタノール20mlに溶
解した。この溶液を75%メタノールを移動相とした分
取高速液体クロマトグラフィー[使用装置:センシュー
科学社製3110;カラム:センシューパックODS−
5251−N(20φ×250mm)]を用い、UV吸
収220nmでモニターしながら流速10ml/min
条件で33分前後に溶出されるピークを分取した。分取
で得られた区分を合わせ減圧濃縮し、メタノールを除去
した後、半量の酢酸エチルで2回抽出した。この酢酸エ
チル抽出区分を合わせ無水硫酸ナトリウムで脱水後、減
圧濃縮乾固した。この操作で得られた粉末を少量のメタ
ノールに溶解し、セファデックスLH−20(商品名;
ファルマシア社製)を用い、メタノールでゲル濾過し、
得られた活性区分を集め減圧濃縮乾固してAF−110
の淡黄色粉末35mgを得た。[0017] This brown syrup was mixed with 200 m of chloroform.
500% of silica gel [Wako Gel C-200 (trade name, manufactured by Wako Pure Chemical Industries, Ltd.)] prepared with chloroform and dissolved in
It was adsorbed onto a ml column. After washing with 500 ml of chloroform, this fraction was removed by elution with a mixed solvent of chloroform-methanol (95:5). Next, chloroform-
Elution was performed with a mixed solvent of methanol (90:10), and each fraction (20 g) was fractionated using a fraction collector. After confirming the antibacterial activity of each fraction against Candida albicans by the paper disc method, the fractions with recognized activity were collected and concentrated to dryness under reduced pressure to obtain 1.5 g of crudely purified powder of AF-110. Crude powder of AF-110 obtained by silica gel column purification was dissolved in 20 ml of methanol. This solution was subjected to preparative high performance liquid chromatography using 75% methanol as a mobile phase [equipment used: Senshu Kagaku Co., Ltd. 3110; column: Senshu Pack ODS-
5251-N (20φ x 250 mm)] at a flow rate of 10 ml/min while monitoring with UV absorption at 220 nm.
A peak eluted around 33 minutes under these conditions was fractionated. The fractions obtained by fractionation were combined and concentrated under reduced pressure to remove methanol, and then extracted twice with half the volume of ethyl acetate. The ethyl acetate extracted fractions were combined, dehydrated with anhydrous sodium sulfate, and then concentrated to dryness under reduced pressure. The powder obtained by this operation was dissolved in a small amount of methanol, and Sephadex LH-20 (trade name;
gel filtration with methanol using
The obtained active fractions were collected and concentrated to dryness under reduced pressure to obtain AF-110.
35 mg of pale yellow powder was obtained.
【0018】試験例1 [抗菌作用試験]実施例で得
たAF−110の1000ug/mlメタノール溶液を
目的濃度となるようメタノールで希釈し、ペーパーディ
スクに浸み込ませた後、約1時間風乾させた。このペー
パーディスクを、細菌用培地としては感受性ティスク寒
天培地を、また真菌用培地としてはサブロー寒天培地を
用い、イノキュラムサイズ106CFU/mlになるよ
う加え調製した試験菌プレートにはり、室温で約1時間
放置後、細菌は37℃で18時間又真菌は25℃で48
〜72時間培養し、培養後の阻止円を測定することによ
り各種菌に対する増殖抑制作用の強さを求め表2の結果
を得た。Test Example 1 [Antibacterial Effect Test] The 1000 ug/ml methanol solution of AF-110 obtained in the example was diluted with methanol to the desired concentration, soaked into a paper disk, and then air-dried for about 1 hour. I let it happen. This paper disk was placed on a test bacterium plate prepared by adding sensitive Tisk agar medium as a bacterial medium and Sabouraud agar medium as a fungal medium to give an inoculum size of 106 CFU/ml, and the plate was placed at room temperature for approximately 1. After standing for 18 hours at 37℃ for bacteria and 48 hours at 25℃ for fungi.
The strength of the growth inhibitory effect on various bacteria was determined by culturing for ~72 hours and measuring the inhibition zone after culturing, and the results shown in Table 2 were obtained.
【0019】[0019]
【表2】[Table 2]
【0020】試験例2 [抗腫瘍作用試験](検体)
実施例で得たAF−110 10mgをメタノールに
溶解し、目的濃度になるようPBS(−)で希釈し用い
た。
(試験細胞)
P388 マウス白血病
K−562 ヒト骨髄白血病
HL−60 ヒト白血病
(使用培養液)
RPM1−1640培地
(試験方法)
前記培養液を用いて各種癌細胞を、2×104〜1×1
05/mlとし、直径35mmの6穴シャーレに2ml
ずつ分注した。次いで目的濃度にあらかじめ希釈した検
体50ulを培養開始と同時に添加した。試験細胞は、
37℃、5%炭酸ガス培養器内で3〜4日間培養を続け
た後、生細胞を測定し、試料濃度と阻害率から、IC5
0値(50%阻害のための濃度)を求め表3の結果を得
た。Test Example 2 [Antitumor Effect Test] (Sample) 10 mg of AF-110 obtained in the example was dissolved in methanol, diluted with PBS (-) to the desired concentration, and used. (Test cells) P388 Mouse leukemia K-562 Human bone marrow leukemia HL-60 Human leukemia (Culture solution used) RPM1-1640 medium (Test method) Using the above culture solution, various cancer cells were cultured at 2 x 104 to 1 x 1
05/ml, and put 2ml into a 6-hole petri dish with a diameter of 35mm.
Dispensed in portions. Then, 50 ul of the specimen previously diluted to the desired concentration was added at the same time as the start of the culture. The test cells are
After continuing to culture in a 5% carbon dioxide incubator at 37°C for 3 to 4 days, live cells were measured and IC5 was determined from the sample concentration and inhibition rate.
The 0 value (concentration for 50% inhibition) was determined and the results shown in Table 3 were obtained.
【0021】[0021]
【表3】[Table 3]
【図1】メタノール溶液中で測定したAF−110の紫
外線吸収スペクトルを示す。FIG. 1 shows the ultraviolet absorption spectrum of AF-110 measured in methanol solution.
【図2】臭化カリウム錠中で測定したAF−110の赤
外線吸収スペクトルを示す。FIG. 2 shows the infrared absorption spectrum of AF-110 measured in potassium bromide tablets.
【図3】重ジメチルスルホオキサイド中、400MHz
で測定したAF−110の1H−NMRスペクトルを示
す。[Figure 3] 400MHz in heavy dimethyl sulfoxide
The 1H-NMR spectrum of AF-110 measured in is shown.
【図4】重ジメチルスルホオキサイド中、100MHz
で測定したAF−110の13C−NMRスペクトルを
示す。[Figure 4] 100MHz in heavy dimethyl sulfoxide
The 13C-NMR spectrum of AF-110 measured in is shown.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3182111A JPH04321684A (en) | 1991-04-22 | 1991-04-22 | 2-pyridone compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3182111A JPH04321684A (en) | 1991-04-22 | 1991-04-22 | 2-pyridone compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04321684A true JPH04321684A (en) | 1992-11-11 |
Family
ID=16112527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3182111A Pending JPH04321684A (en) | 1991-04-22 | 1991-04-22 | 2-pyridone compound |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04321684A (en) |
-
1991
- 1991-04-22 JP JP3182111A patent/JPH04321684A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3854866B2 (en) | Method for producing mycophenolic acid and derivatives thereof | |
| JPH0368570A (en) | Fungicide | |
| JPH04321684A (en) | 2-pyridone compound | |
| JP4380913B2 (en) | Novel FT-0554 substance and production method thereof | |
| JPH0532656A (en) | Decalin compound | |
| CN102851218B (en) | Production method of 11-O-acetylcyathatriol and 15-O-acetylcyathatriol, and special bacterial strain thereof | |
| JPH0429995A (en) | New antibiotic substance wf3010 and its production | |
| JPH083097A (en) | Benzophenone compound FD-549 | |
| JP3067904B2 (en) | A new penicillium mold | |
| JPH0314588A (en) | Physiologically active compound 3822a and b | |
| JPS6265685A (en) | Physiologically active substance fd-838 and production thereof | |
| JPH05255184A (en) | New compound ilicicolinic acid a or b | |
| JPH1112296A (en) | Antifungal compound AFA0424 | |
| JPS6143182A (en) | Novel antibiotic ss19508d and preparation thereof | |
| JPH04321698A (en) | Physiologically active substance m6124 and production thereof | |
| JPH0446188A (en) | New antibiotic pf1032b substance and production thereof | |
| JPH0341089A (en) | Physiologically active substance 3127 | |
| JPWO1994012175A1 (en) | Lipid-lowering agents containing penicillide compounds as active ingredients | |
| JPS5889187A (en) | No14-a substance and its preparation | |
| JPH06172378A (en) | Steroid compound | |
| JPH03201991A (en) | New antibiotic pf1042 substance and production thereof | |
| JPH03169881A (en) | Substance for suppressing proliferation of cancer cell | |
| JPH0859612A (en) | Antibiotics AB4015-A1, A2 and A3, their production method and agricultural and horticultural fungicides | |
| JPH05239023A (en) | Physiologically active substance MBP039-06 and method for producing the same | |
| JPH0310689A (en) | Physiologically active substance fd-839 |